Psilocybin program

Mental healthcare biotech company advancing psilocybin therapy COMPASS Pathways plc (NASDAQ: CMPS) reported its financial results for the first quarter 2023 ended March 31, 2023 and updated on recent business and clinical progresses. In numbers: Cash and cash equivalents totaled $117.1 million as...

Fully-integrated biopharma company Albert Labs International Corp.’s international patent application covering IP around a novel manufacturing technology for the production and scaling of fungi biomass yields including psilocybin has received preliminary acceptance by the World International...

Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin is a constitutional right under the Canadian Charter of Rights and Freedoms. In 2020, Health...

Psychotherapists at the Massachusetts General Hospital (MGH) have undergone training by lead business Fluence toward participating in Tryp Therapeutics (OTCQB: TRYPF)’ Phase 2a trial assessing psilocybin-assisted psychotherapy on adult participants with treatment-resistant Irritable Bowel...

The natural psychedelics company responsible for creating the first standardized ayahuasca capsule, Filament Health Corp. (OTCQB: FLHLF), shared its financial results and operational highlights for the period ended December 31, 2022. Numbers show: Total cash of $2.08 (CA$2.8) million as of...

COMPASS Pathways' (NASDAQ: CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant Depression (TRD) is still nourishing the psychedelics research field, as newly published data demonstrate the therapy’s potential beyond the...

The exclusive sales partnership between psychedelics biotechs Mindset Pharma (OTCQB: MSSTF) and PharmAla Holdings resulted in the first sale of Mindset’s GMP-compliant psilocybin in Australia. The psilocybin batch was purchased by Reset Mind Sciences Ltd., a Western Australian-based...

Mental healthcare biotech COMPASS Pathways (NASDAQ: CMPS) reported its financial results for the fourth quarter and year-end 2022 and provided an update on recent pipeline and business progress. Numbers show: Cash and cash equivalents of $143.2 million as of Dec. 31, 2022, compared to $273.2...

A new clinical trial assessed the immediate acute effects of 2C-B hallucinogenic phenethylamine compared to psilocybin on subjective experience, mood and cognition. The study, conducted by Netherlands’ University of Maastricht, had a total of 22 psychedelic-experienced volunteers divided into...

Oklahoma To Reconsider Bills On Psilocybin Therapy Research Together with several other state legislatures, it is now Oklahoma’s turn to dive in with the relaunch of a 2022 proposal involving psychedelics. Last year, HB 3414 was amended but ultimately killed. However, sponsor Rep. Daniel Pae...

Filament’s Psilocybin, Tested On Mild Cognitive Impairment By CAMH Clinical-stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) has inked a second supply deal with Canada-based Centre for Addiction and Mental Health (CAMH) concerning its botanical...

Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a genetic disorder. KGK and its client Nova Mentis (OTC: NMLSF) are set to conduct this pioneering...

Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More Hawaii: A bill to establish the Therapeutic Psilocybin Working Group, to study psychedelics' medicinal and therapeutic effects, has been approved with recommended amendments. The measure won support from Democratic...

A new open-label study Sponsored by King’s College London (KCL) will assess the effects of a single psilocybin dose of 25 milligram on subjects with a diagnosis of the common and disabling Functional Neurological Disorder (FND). The National Institutes of Health (NIH) defines this...

Licensed psychedelic drugs producer Optimi Health Corp. (OTCQX: OPTHF) submitted a Health Canada clinical trial application (CTA) for a Phase 1 study that will assess the safety of combining its natural psilocybin standardized extract with its proprietary MDMA drug candidate in healthy therapists....